Fragment and Structure-Based Drug Discovery for a Class C GPCR

Heptares Therapeutics are regular users of Diamond's microfocus MX beamline, I24, to investigate GPCR structures.  Their latest publication looks at fragment and structure-based drug discovery methods using a Class C GPCR.  

John A. Christopher et al., Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile), 2015, J. Med. Chem. DOI: 10.1021/acs.jmedchem.5b00892